IL325596A - תכשירי רוקחות למעכבים של nek7 קינאז - Google Patents

תכשירי רוקחות למעכבים של nek7 קינאז

Info

Publication number
IL325596A
IL325596A IL325596A IL32559625A IL325596A IL 325596 A IL325596 A IL 325596A IL 325596 A IL325596 A IL 325596A IL 32559625 A IL32559625 A IL 32559625A IL 325596 A IL325596 A IL 325596A
Authority
IL
Israel
Prior art keywords
nek7
kinase
inhibitors
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
IL325596A
Other languages
English (en)
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of IL325596A publication Critical patent/IL325596A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
IL325596A 2023-07-06 2025-12-24 תכשירי רוקחות למעכבים של nek7 קינאז IL325596A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363512188P 2023-07-06 2023-07-06
US202463657018P 2024-06-06 2024-06-06
PCT/US2024/036944 WO2025010421A1 (en) 2023-07-06 2024-07-05 Pharmaceutical compositions for inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
IL325596A true IL325596A (he) 2026-02-01

Family

ID=92108588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325596A IL325596A (he) 2023-07-06 2025-12-24 תכשירי רוקחות למעכבים של nek7 קינאז

Country Status (7)

Country Link
KR (1) KR20260033582A (he)
CN (1) CN121793970A (he)
AU (1) AU2024290795A1 (he)
CO (1) CO2026000093A2 (he)
IL (1) IL325596A (he)
TW (1) TW202517271A (he)
WO (1) WO2025010421A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202539650A (zh) * 2024-01-25 2025-10-16 美商哈利亞製藥公司 治療疼痛的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991366T3 (es) * 2020-05-08 2024-12-03 Halia Therapeutics Inc Inhibidores de NEK7 cinasa

Also Published As

Publication number Publication date
CO2026000093A2 (es) 2026-01-23
TW202517271A (zh) 2025-05-01
KR20260033582A (ko) 2026-03-10
CN121793970A (zh) 2026-04-03
WO2025010421A1 (en) 2025-01-09
AU2024290795A1 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
ZA202212146B (en) Inhibitors of nek7 kinase
IL317985A (he) תכשירים פרמצבטיים הכוללים מעכבי הליקס של wrn
IL317988A (he) תכשירים פרמצבטיים הכוללים מעכבי הליקס של
IL320739A (he) מעכבי rock2
IL325596A (he) תכשירי רוקחות למעכבים של nek7 קינאז
IL315722A (he) תרכובות אינדאזול מותמרות עם פיפראזין כמעכבי parg
EP4076395A4 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
IL326424A (he) תרכובות ותכשירים פרמצבטיים כמעכבי c-kit קינאז
IL316616A (he) מעכבי rock2
IL317736A (he) תרכובות כמעכבות של axl
IL288387A (he) מעכבי מוליקולות קטנות של קינאז גורם nf-kb
IL306022A (he) מעכבי אינפלמוזום nlrp3
IL314397A (he) מעכבים של cdk4/6 קינאז
IL313548A (he) מעכבי met קינאז
IL308071A (he) תהליך להכנת מעכבי nlrp3
IL309447A (he) תכשירי רוקחות של מעכב קולטן גורם גדילה אפידרמלי
HUE072981T2 (hu) Azakinolinok mint CD38 gátlók
EP4452967A4 (en) Inhibitors of sars-cov-2
IN202221071152A (en) Extended-release pharmaceutical compositions of dydrogestrone
CA3297265A1 (en) Pharmaceutical compositions for inhibitors of nek7 kinase
TWI923584B (zh) Ｎｅｋ７激酶抑制劑
IL308513A (he) מעכבי קינאז alk2 המכילים אימידאזולים
HK40088585A (en) Inhibitors of nek7 kinase
GB202100470D0 (en) Solid tablet dosage for of ridinilazole
CA3301042A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors